Dapagliflozin
Brand: Forxiga®
NICE TA: 418
Indication: Triple therapy for treating type 2 diabetes (NICE TA418)
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No
Background
Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.
The LMMG recommends dapagliflozin as a 1st line ““gliflozin””.
Recommendation
LMMG recommendation: Green
Click here to find the definitions for the colour classifications
Reason for decision: Suitable for initiation in primary care
Supporting documents:
NICE TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes
Algorithm For Antihyperglycaemic Therapy In Adults With Type II (Version 1.5) (454.0 KiB)
Decisions of Lancashire local decision making groups:
| NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
|---|---|---|---|---|---|
Green |
Green |
Green |
Green |
Green |
Green |
